Full Text
Estimating The Budget Impact Of Adding Omalizumab To Standard Therapy In Patients With Uncontrolled Severe Allergic Asthma From Private Health Care System Perspective In Brazil

Abstract

Authors

C. Suzuki N.B. Santoni N.L. Silva

Back to Volume 16, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×